Company intelligence / Profile preview

Insera Therapeutics

Sacramento, California, United Statesinseratherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Insera’s CLEAR Aspiration System has demonstrated successful first-in-human use for both acute ischemic stroke and pulmonary embolism, showing improved recanalization rates and reduced distal embolization compared to traditional systems. The system received CE Mark approval in March 2019, allowing commercial use in Europe.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceNon-pharmacological therapy (aspiration system)
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

CLEAR Aspiration System

Pre-clinical

Indications: Stroke

1 more asset in the full pipeline.

Request access →

Partnerships

National Science Foundation as a grant funder/investor

Beyond the preview

Go deeper on Insera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insera Therapeutics.

Explore the full profile